Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Focal Segmental Glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome in adults, with steroid responsiveness being the most dependable predictor of long-term outcomes. Data on the natural history of adult FSGS in India are limited. We report 1-year outcomes of adults with primary FSGS treated with oral prednisolone and enrolled in the pan-India I-TANGIBLE Registry.
I-TANGIBLE is an ICMR-funded collaborative registry across 13 centres in India, enrolling adult patients with biopsy-proven GN. A total of 621 FSGS patients were recruited between June 2022 and June 2025. One-year follow-up data were available for 184 patients; all the patients treated with prednisolone had nephrotic syndrome. Adjunctive therapy included ACE inhibitors/ARBs and other immunosuppressive agents as clinically indicated. Follow-up assessments at 3, 6, and 12 months included proteinuria, serum albumin, serum creatinine, steroid response, relapse, and complications. Remission was defined per KDIGO guidelines.
A total of 184 patients (100 males, 84 females) with a mean age of 33.38 ±15.2 years were analysed. At baseline, median proteinuria was 4.73 (3.2,6.75) g/day, mean serum albumin 2.49 ±1.7 [median :2.2, (1.7,3) g/dL], and median serum creatinine 0.98 (0.7,1.67) mg/dL. At 12 months, median proteinuria decreased to 0.8 (0.26,1.56) g/day, serum albumin increased to 3.67 ± 0.88 g/dL, and serum creatinine remained stable at 0.89 (0.7,1.165) mg/dL. Overall, 155 (84.2%) patients achieved while 29 (15.8%) were steroid resistant. Relapse occurred in 38 (20.6%) patients, with a median time to relapse of 6 months. 56 (30.43%) patients required second line therapy (30 CNI, 21 RTX,5 MMF, CYC etc.) Treatment-related complications were noted in 30 (16.3%) patients.
Among Indian adults with FSGS and nephrotic syndrome treated with prednisolone, most achieved clinical remission within one year. These findings provide important insights into the short-term outcomes of FSGS in India. Nearly one-third required additional immunosuppressive therapy to maintain remission.
